Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing liquid biopsies into clinical decision making for cancer immunotherapy.
Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B. Quandt D, et al. Among authors: nayak t. Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Oncotarget. 2017. PMID: 28501851 Free PMC article. Review.
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C. Menke-van der Houven van Oordt CW, et al. Among authors: nayak tk. Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098. Oncotarget. 2016. PMID: 27507056 Free PMC article. Clinical Trial.
89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.
van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW. van Brummelen EMJ, et al. Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15. Oncotarget. 2018. PMID: 29872502 Free PMC article.
PET imaging to monitor cancer therapy.
Malviya G, Nayak TK. Malviya G, et al. Curr Pharm Biotechnol. 2013;14(7):669-82. doi: 10.2174/1389201014666131226104750. Curr Pharm Biotechnol. 2013. PMID: 24372238 Review.
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
Griessinger CM, Olafsen T, Mascioni A, Jiang ZK, Zamilpa C, Jia F, Torgov M, Romero JM, Marchioni F, Satpayev D, Lee C, Zhang G, Nayak TK, Pincha M, Amann M, Mohan PLB, Richard M, Nicolini VG, Sam J, Claus C, Ferrara C, Brünker P, Bacac M, Umana P, Rüttinger D, Wilson IA, Gudas J, Klein C, Tessier JJL. Griessinger CM, et al. Among authors: nayak tk. Cancer Res. 2020 Jul 1;80(13):2903-2913. doi: 10.1158/0008-5472.CAN-19-3269. Epub 2020 May 14. Cancer Res. 2020. PMID: 32409308
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, Schoenle A, Karagianni M, Le Clech M, Steinhoff N, Klein C, Umaña P, Bacac M. Sam J, et al. Among authors: nayak t. Front Oncol. 2021 Feb 3;11:650149. doi: 10.3389/fonc.2021.650149. eCollection 2021. Front Oncol. 2021. PMID: 33614518 Free PMC article.
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA. Pastuskovas CV, et al. Mol Cancer Ther. 2012 Mar;11(3):752-62. doi: 10.1158/1535-7163.MCT-11-0742-T. Epub 2012 Jan 5. Mol Cancer Ther. 2012. PMID: 22222630
315 results